Abstract

Toxoplasma gondii (T. gondii) is an obligate intracellular parasite with the capacity to infect almost any warm blood animal; it’s transmitted to humans in several ways, such as transplacental spread. Most congenitally-infected children are free of symptoms at birth, however among infected newborns 40% have neurological sequelae. Involvement of hypothalamic-pituitary axis is uncommon, when it occurs it usually affects the anterior pituitary and exceptionally the posterior pituitary. In this article we present the case of an infant with congenital toxoplasmosis and central diabetes insipidus, referred to a tertiary care center in Mexico City.

Keywords: Congenital Toxoplasmosis; Central Nervous System; Hypothalamic-Pituitary Axis; Central Diabetes Insipidus

References

1. Khadija K and Wajihullah K. “Congenital toxoplasmosis: An overview of neurological and ocular manifestations”. International Journal for Parasitology 67 (2018): 715-721.
2. Robert-Gangneux F and Darde ML. “Epidemiology of and diagnostic strategies for toxoplasmosis”. Journal of Clinical Microbiology 25.2 (2012): 264-296.
3. Hernández-Cortazar I., et al. “Toxoplasmosis IN mexico: Epidemiological Situation in Humans and Animals”. The Revista do Instituto de Medicina Tropical de São Paulo 57.2 (2015): 93-103. 
4. Kaplan JE., et al. “Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America”. MMWR Recommendations and Reports 58.4 (2009): 1-207. 
5. Hernández-Cortazar I., et al. “Toxoplasmosis IN mexico: Epidemiological Situation in Humans and Animals”. The Revista do Instituto de Medicina Tropical de São Paulo 57.2 (2015): 93-103. 
6. Oz HS. “Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon”. Frontiers in Microbiology 5 (2014): 385. 
7. Torgerson PR and Mastroiacovo P. “The global burden of congenital toxoplasmosis: a systematic review”. Bulletin of the World Health Organization 91.7 (2013): 501-508.
8. Robert-Ganneux F and Dardé ML. “Epidemiology and diagnostic strategies for toxoplasmosis”. Clinical Microbiology Reviews 25.2 (2012): 264.
9. Mohamed S., et al. “Congenital toxoplasmosis presenting as central diabetes insipidus in an infant: a case report”. BMC Research Notes 7 (2014): 184.
10. Sarkari B., et al. “Seroprevalence and molecular diagnosis of Toxoplasma gondii infection among blood donors in southern Iran”. Journal of Infection in Developing Countries 8.4 (2014): 543-547.
11. Mohanty S., et al. “Neonatal hepatitis with toxoplasmosis”. Journal of Clinical Neonatology 1.2 (2012): 96-97. 
12. Kairam R and DeVivo DC. “Neurologic manifestations of congenital infection”. Clinics in Perinatology 8 (1981): 445-465.
13. Masa G., et al. “Hypothalamo-pituitary dysfunction in congenital toxoplasmosis”. European Journal of Pediatrics 148 (1989): 742-744.
14. Coppola A., et al. “Ipopituitarismo anteriore parziale da txoplasmosi congénita”. Minerva Medica 78 (1987): 403-410. 
15. Giacchino M., et al. “Su di una rarissima associazione di processi morbosi: difetto di HGH, toxoplasmosi, situs inversus, malformazioni renali ed altri”. Minerva Pediatrica 29 (1977): 1879-1888.
16. Steendijk R. “Diagnostic and aetiologic features of idiopathic and symptomatic growth hormone deficiency in Netherlands”. Helvetica Chimica Acta 35 (1980): 129-139.
17. Wilson CB., et al. “Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection”. Pediatrics 66 (1980): 767-774.
18. Karadag A and Erdeve O. “Isolated central diabetes insipidus in a newborn with congenital toxoplasmosis”. Journal of Pediatric Endocrinology and Metabolism 19.2 (2006): 173-175.
19. Oygür N., et al. “Central diabetes insipidus in a patient with congenital toxoplasmosis”. The American Journal of Dermatopathology 15.3 (1998): 191-192.
20. Rivas-Crespo MF., et al. “Rare neonatal insipidus and associated late risks: Case report”. BMC Pediatrics 12 (2012): 56. 
21. Cheetham T and Baylis PH. “Diabetes Insipidus in Children. Pathophysiology, Diagnosis and Management”. Pediatric Drugs 4 (2002): 785-796. 
22. Jarosz-Lesz A and Maruniak-Chudek I. “Copeptin - stable C-terminal fragment of pre-provasopressin as a new stress marker in newborns”. Postepy Higieny I Medycyny Doswiadczalnej 69 (2015): 681-689.
23. Blanco EJ., et al. “Use of Subcutaneous DDAVP in Infants with Central Diabetes Insipidus”. Journal of Pediatric Endocrinology and Metabolism 19 (2006): 919-925.